Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delayed-Start Extension Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (AMARANTH Extension)
2016-003440-36Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lanabecestat in Alzheimer's disease (AD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Delayed-start analysis on the ADAS-Cog13. Started Apr 2017; status: completed.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2016-003440-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003440-36.